{"id":"anti-pd-l1-antibody-atezolizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hypothyroidism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Atezolizumab is a monoclonal antibody that binds to programmed death ligand 1 (PD-L1) on the surface of tumor cells and immune cells. By blocking the PD-L1/PD-1 interaction, it removes a key immune evasion mechanism that cancers use to hide from the immune system. This restores T cell activation and proliferation, enabling the body's own immune system to recognize and eliminate cancer cells.","oneSentence":"Atezolizumab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:56:45.728Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Urothelial carcinoma"},{"name":"Triple-negative breast cancer"},{"name":"Other solid tumors (phase 2 evaluation)"}]},"trialDetails":[{"nctId":"NCT04660344","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-03","conditions":"Muscle-invasive Bladder Cancer","enrollment":761},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT04102098","phase":"PHASE3","title":"A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-12-31","conditions":"Carcinoma, Hepatocellular","enrollment":668},{"nctId":"NCT04902040","phase":"PHASE1, PHASE2","title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-14","conditions":"Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm","enrollment":19},{"nctId":"NCT04458922","phase":"PHASE2","title":"Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-10-05","conditions":"Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma","enrollment":27},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT05047250","phase":"PHASE3","title":"A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-14","conditions":"Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT04020809","phase":"PHASE1","title":"Neoadjuvant Atezolizumab in Cutaneous Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2020-09-25","conditions":"Cutaneous Melanoma","enrollment":20},{"nctId":"NCT02705196","phase":"PHASE1, PHASE2","title":"LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer","status":"COMPLETED","sponsor":"Lokon Pharma AB","startDate":"2016-11","conditions":"Pancreatic Cancer","enrollment":51},{"nctId":"NCT02846623","phase":"PHASE2","title":"Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-01-31","conditions":"Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia","enrollment":50},{"nctId":"NCT02486718","phase":"PHASE3","title":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2015-10-31","conditions":"Non-Small Cell Lung Cancer","enrollment":1280},{"nctId":"NCT05733611","phase":"PHASE2","title":"RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC","status":"TERMINATED","sponsor":"Replimune Inc.","startDate":"2023-06-29","conditions":"Refractory Metastatic Colorectal Cancer, pMMR, MSS","enrollment":5},{"nctId":"NCT04294810","phase":"PHASE3","title":"A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-03-04","conditions":"Non-Small Cell Lung Cancer","enrollment":620},{"nctId":"NCT04661150","phase":"PHASE2","title":"A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-12","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":42},{"nctId":"NCT06254911","phase":"PHASE2","title":"Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma","status":"SUSPENDED","sponsor":"Emory University","startDate":"2023-10-27","conditions":"Oropharynx Cancer, Stage I","enrollment":20},{"nctId":"NCT03456063","phase":"PHASE3","title":"A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-04-24","conditions":"Non-Small-Cell Lung","enrollment":453},{"nctId":"NCT07166406","phase":"PHASE3","title":"Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-10-07","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":252},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT04471428","phase":"PHASE3","title":"Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-10-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":366},{"nctId":"NCT06908993","phase":"PHASE3","title":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-12-09","conditions":"Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation","enrollment":133},{"nctId":"NCT05733598","phase":"PHASE2","title":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT05393713","phase":"PHASE1","title":"Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2022-10-17","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma","enrollment":3},{"nctId":"NCT04276376","phase":"PHASE2","title":"Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-04-12","conditions":"Solid Tumor","enrollment":130},{"nctId":"NCT07246668","phase":"PHASE2","title":"A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2025-03-10","conditions":"Hepatocellular Carcinoma, Liver Neoplasms, Carcinoma","enrollment":52},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT05468489","phase":"PHASE3","title":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-11-18","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT03141684","phase":"PHASE2","title":"Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-25","conditions":"Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma","enrollment":63},{"nctId":"NCT02982694","phase":"PHASE2","title":"Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer","status":"TERMINATED","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2017-11-24","conditions":"MSI, ColoRectal Cancer, Chemotherapy","enrollment":46},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT04808245","phase":"PHASE1","title":"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-02-15","conditions":"Newly Diagnosed H3-mutated Glioma","enrollment":15},{"nctId":"NCT03271372","phase":"PHASE3","title":"Adjuvant Avelumab in Merkel Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2017-12-19","conditions":"Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8","enrollment":101},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT07130032","phase":"PHASE2","title":"Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade","status":"RECRUITING","sponsor":"EuroCityClinic LLC","startDate":"2025-08-14","conditions":"Metastatic Non-small Cell Lung Cancer (NSCLC), Metastatic Cutaneous Melanoma","enrollment":90},{"nctId":"NCT05222932","phase":"PHASE1","title":"Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1","status":"ACTIVE_NOT_RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2023-03-08","conditions":"Melanoma, Head and Neck Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT03289962","phase":"PHASE1","title":"A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2017-12-21","conditions":"Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer","enrollment":272},{"nctId":"NCT04356729","phase":"PHASE2","title":"A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elizabeth Buchbinder, MD","startDate":"2020-08-06","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma","enrollment":30},{"nctId":"NCT04442126","phase":"PHASE1, PHASE2","title":"A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Numab Therapeutics AG","startDate":"2020-08-19","conditions":"Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":52},{"nctId":"NCT05482516","phase":"PHASE3","title":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2023-03-29","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma","enrollment":20},{"nctId":"NCT03212469","phase":"PHASE1, PHASE2","title":"A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-06-20","conditions":"Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer","enrollment":54},{"nctId":"NCT02902029","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2016-11","conditions":"Malignant Melanoma","enrollment":186},{"nctId":"NCT03829501","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies","status":"TERMINATED","sponsor":"Kymab Limited","startDate":"2019-01-28","conditions":"Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma","enrollment":222},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT04962126","phase":"PHASE2","title":"Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2021-08-17","conditions":"Follicular Lymphoma","enrollment":15},{"nctId":"NCT06867432","phase":"PHASE2","title":"Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-01","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT02807636","phase":"PHASE3","title":"Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-06-30","conditions":"Urothelial Carcinoma","enrollment":1213},{"nctId":"NCT03272217","phase":"PHASE2","title":"Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer","status":"TERMINATED","sponsor":"Arjun Balar, MD","startDate":"2017-09-13","conditions":"Urothelial Carcinoma","enrollment":16},{"nctId":"NCT05937295","phase":"PHASE1","title":"FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-09-26","conditions":"Fibrolamellar Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT06702566","phase":"NA","title":"The Effect of Serum Ferritin in irAE","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-04","conditions":"Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia","enrollment":1500},{"nctId":"NCT04989218","phase":"PHASE1, PHASE2","title":"Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2023-01-30","conditions":"Cholangiocarcinoma","enrollment":1},{"nctId":"NCT04504669","phase":"PHASE1","title":"First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":"Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms","enrollment":60},{"nctId":"NCT03191786","phase":"PHASE3","title":"A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-09-11","conditions":"Non-Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT03452137","phase":"PHASE3","title":"A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-04-03","conditions":"Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)","enrollment":406},{"nctId":"NCT05191797","phase":"PHASE1, PHASE2","title":"Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer","status":"TERMINATED","sponsor":"University of Washington","startDate":"2022-04-11","conditions":"Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma","enrollment":3},{"nctId":"NCT04123470","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma","status":"COMPLETED","sponsor":"Lokon Pharma AB","startDate":"2020-01-28","conditions":"Malignant Melanoma","enrollment":24},{"nctId":"NCT02927301","phase":"PHASE2","title":"A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2017-04-20","conditions":"Non-Small Cell Lung Cancer","enrollment":181},{"nctId":"NCT03498716","phase":"PHASE3","title":"A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-02","conditions":"Triple Negative Breast Cancer","enrollment":2199},{"nctId":"NCT03016312","phase":"PHASE3","title":"A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-10","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":759},{"nctId":"NCT05878691","phase":"PHASE1","title":"A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Glenmark Specialty S.A.","startDate":"2022-06-28","conditions":"Advanced Solid Tumor, Lymphoma","enrollment":320},{"nctId":"NCT03046953","phase":"PHASE2","title":"Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma","status":"COMPLETED","sponsor":"University of Birmingham","startDate":"2017-12-08","conditions":"T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory","enrollment":35},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT04426825","phase":"PHASE2","title":"A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-09-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":23},{"nctId":"NCT02992912","phase":"PHASE2","title":"Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-11-15","conditions":"Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )","enrollment":138},{"nctId":"NCT02478099","phase":"PHASE2","title":"MPDL3280A-treatment-IST-UMCG","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2016-02-24","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":81},{"nctId":"NCT04147351","phase":"PHASE2","title":"A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-04-10","conditions":"NSCLC Stage IIIB~IV","enrollment":22},{"nctId":"NCT03281954","phase":"PHASE3","title":"Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo","status":"ACTIVE_NOT_RECRUITING","sponsor":"NSABP Foundation Inc","startDate":"2017-12-19","conditions":"Triple Negative Breast Cancer","enrollment":1550},{"nctId":"NCT03125902","phase":"PHASE3","title":"A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-25","conditions":"Triple-Negative Breast Cancer","enrollment":653},{"nctId":"NCT04274023","phase":"PHASE2","title":"Study on TSR-042 in Advanced Clear Cell Sarcoma","status":"TERMINATED","sponsor":"Italian Sarcoma Group","startDate":"2024-01-29","conditions":"Sarcoma, Clear Cell","enrollment":3},{"nctId":"NCT06194695","phase":"","title":"DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Ze-yang Ding, MD","startDate":"2022-02-01","conditions":"Cholangiocarcinoma Non-resectable","enrollment":100},{"nctId":"NCT05492123","phase":"PHASE2","title":"Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer","status":"RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2022-08-30","conditions":"Uterine Cervical Neoplasms","enrollment":112},{"nctId":"NCT02657434","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-04-30","conditions":"Non-Small Cell Lung Cancer","enrollment":578},{"nctId":"NCT02733042","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-05-11","conditions":"Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":106},{"nctId":"NCT03197935","phase":"PHASE3","title":"A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-24","conditions":"Triple-negative Breast Cancer","enrollment":333},{"nctId":"NCT05069935","phase":"PHASE1","title":"FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors","status":"TERMINATED","sponsor":"Fate Therapeutics","startDate":"2021-10-15","conditions":"Solid Tumor, Adult","enrollment":16},{"nctId":"NCT03390296","phase":"PHASE1, PHASE2","title":"OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-27","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT03961698","phase":"PHASE2","title":"Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Infinity Pharmaceuticals, Inc.","startDate":"2019-12-17","conditions":"Breast Cancer, Renal Cell Carcinoma","enrollment":91},{"nctId":"NCT05390528","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-06-20","conditions":"Advanced Tumors, Lymphoma, Metastatic Tumors","enrollment":30},{"nctId":"NCT05102214","phase":"PHASE1, PHASE2","title":"HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-05-03","conditions":"Locally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer","enrollment":150},{"nctId":"NCT03024996","phase":"PHASE3","title":"A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-03","conditions":"Renal Cell Carcinoma","enrollment":778},{"nctId":"NCT02763579","phase":"PHASE3","title":"A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-06-07","conditions":"Small Cell Lung Carcinoma","enrollment":503},{"nctId":"NCT02450331","phase":"PHASE3","title":"A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-05","conditions":"Carcinoma, Transitional Cell","enrollment":809},{"nctId":"NCT04471415","phase":"PHASE1, PHASE2","title":"Study to Investigate DRP-104 in Adults With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Dracen Pharmaceuticals, Inc.","startDate":"2020-08-31","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic","enrollment":61},{"nctId":"NCT03850028","phase":"NA","title":"Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients","status":"WITHDRAWN","sponsor":"University Medical Center Groningen","startDate":"2019-05-22","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","enrollment":""},{"nctId":"NCT04992715","phase":"PHASE2","title":"PD-L1 Expression in Lung Cancer","status":"UNKNOWN","sponsor":"NanoMab Technology (UK) Limited","startDate":"2022-05-03","conditions":"Non-Small Cell Lung Cancer","enrollment":15},{"nctId":"NCT02409342","phase":"PHASE3","title":"A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-07-20","conditions":"Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer","enrollment":572},{"nctId":"NCT02659384","phase":"PHASE2","title":"Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2016-12-23","conditions":"Ovarian Neoplasms","enrollment":122},{"nctId":"NCT03386721","phase":"PHASE2","title":"Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-02-19","conditions":"Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers","enrollment":256},{"nctId":"NCT04107168","phase":"","title":"Microbiome Immunotherapy Toxicity and Response Evaluation","status":"UNKNOWN","sponsor":"CCTU- Cancer Theme","startDate":"2020-07-08","conditions":"Melanoma, Renal Cancer, Lung Cancer","enrollment":1800},{"nctId":"NCT02420821","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05-20","conditions":"Renal Cell Carcinoma","enrollment":915},{"nctId":"NCT02813785","phase":"PHASE3","title":"A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-07-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":565},{"nctId":"NCT03455556","phase":"PHASE1","title":"Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-08-10","conditions":"Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7","enrollment":1},{"nctId":"NCT02400814","phase":"PHASE1","title":"MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Megan Daly, MD","startDate":"2015-12-03","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer","enrollment":27},{"nctId":"NCT02425891","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-06-23","conditions":"Triple Negative Breast Cancer","enrollment":902},{"nctId":"NCT02410512","phase":"PHASE1","title":"A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-04-24","conditions":"Neoplasms","enrollment":610},{"nctId":"NCT02367794","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-06-11","conditions":"Squamous Non-Small Cell Lung Cancer","enrollment":1021},{"nctId":"NCT03922477","phase":"PHASE1","title":"A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2019-10-08","conditions":"Acute Myeloid Leukemia","enrollment":13},{"nctId":"NCT03050814","phase":"PHASE2","title":"Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-05","conditions":"Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":30},{"nctId":"NCT02366143","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-03-31","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1202},{"nctId":"NCT02777710","phase":"PHASE1","title":"Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2016-06","conditions":"Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer","enrollment":48},{"nctId":"NCT03566485","phase":"PHASE1, PHASE2","title":"Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer","status":"TERMINATED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2018-07-10","conditions":"Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-PD-L1 antibody atezolizumab","genericName":"Anti-PD-L1 antibody atezolizumab","companyName":"Gustave Roussy, Cancer Campus, Grand Paris","companyId":"gustave-roussy-cancer-campus-grand-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atezolizumab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer. Used for Non-small cell lung cancer, Urothelial carcinoma, Triple-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}